Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Alemtuzumab

EBV-positive lymphoproliferative disorder: case report

    • 12 Accesses

    This is a preview of subscription content, log in to check access.

    REFERENCE

    1. 1.

      Cooles FAH, Jackson GH, Menon G, Isaacs JD.Epstein-Barr virus-driven lymphoproliferative disorder post-CAMPATH-1H (alemtuzumab) in refractory polymyositis. Rheumatology 50: 810-812, No. 4, Apr 2011. Available from: URL: http://dx.doi.org/10.1093/rheumatology/keq429 - United Kingdom

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Alemtuzumab. React. Wkly. 1350, 9 (2011). https://doi.org/10.2165/00128415-201113500-00016

    Download citation

    Keywords

    • Glycaemic Control
    • Liver Lesion
    • Alemtuzumab
    • Lymphopenia
    • Lymphoproliferative Disorder